Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders
Open Access
- 17 April 2023
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (4) , 603
Abstract
Mental illnesses are a global health challenge, and effective medicines are needed to treat these conditions. Psychotropic drugs are commonly prescribed to manage mental disorders, such as schizophrenia, but unfortunately, they can cause significant and undesirable side effects, such as myocarditis, erectile dysfunction, and obesity. Furthermore, some schizophrenic patients may not respond to psychotropic drugs, a condition called schizophrenia-treatment resistance. Fortunately, clozapine is a promising option for patients who exhibit treatment resistance. Unlike chlorpromazine, scientists have found that clozapine has fewer neurological side effects. Additionally, olanzapine and aripiprazole are well-known for their moderating effects on psychosis and are widely used in clinical practice. To further maximize drug efficacy, it is critical to deeply understand the receptors or signaling pathways central to the nervous system, such as serotonin, histamine, trace amines, dopamine, and G-protein coupled receptors. This article provides an overview of the receptors mentioned above, as well as the antipsychotics that interact with them, such as olanzapine, aripiprazole, clozapine, and chlorpromazine. Additionally, this article discusses the general pharmacology of these medications.Keywords
This publication has 73 references indexed in Scilit:
- An Overview of Animal Models Related to SchizophreniaThe Canadian Journal of Psychiatry, 2018
- Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapineTherapeutic Advances in Drug Safety, 2018
- Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscienceTranslational Psychiatry, 2018
- Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidoneNature, 2018
- Uso de medicamentos psicotrópicos em adultos e idosos residentes em Campinas, São Paulo: um estudo transversal de base populacional*Epidemiologia e Serviços de Saúde, 2017
- Cognition in schizophrenia: core psychological and neural mechanismsTrends in Cognitive Sciences, 2012
- The histamine H3receptor: an attractive target for the treatment of cognitive disordersBritish Journal of Pharmacology, 2008
- Developing translational animal models for symptoms of schizophrenia or bipolar maniaNeurotoxicity Research, 2008
- β-Arrestins and Cell SignalingAnnual Review of Physiology, 2007
- Increased dopamine transmission in schizophrenia: relationship to illness phasesBiological Psychiatry, 1999